What is the main reason for this 10-Q/A filing?

This filing is an amendment (10-Q/A) to correct an error where an incorrect Interactive Data File (Exhibit 101) for a prior period's Form 10-Q was inadvertently filed. It does not reflect new financial performance for the quarter ended June 30, 2010.

Does this filing change Eli Lilly's financial results for the quarter ended June 30, 2010?

No, the filing explicitly states that there have been no changes from the original Form 10-Q other than the correction of the Interactive Data File exhibit. The underlying financial performance remains as previously reported.

What does it mean that Eli Lilly is a 'large accelerated filer'?

Being a large accelerated filer indicates that Eli Lilly meets specific size and filing history requirements set by the SEC, generally meaning it has a significant market capitalization and has been subject to SEC reporting requirements for a substantial period, providing a higher level of transparency to investors.

How many shares of Eli Lilly common stock were outstanding as of the reporting period?

As of July 20, 2010, Eli Lilly had 1,153,140,311 shares of common stock outstanding.

LLY 10-Q Quarterly Report Q2 FY2010 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's (LLY) Form 10-Q/A filed on August 1, 2010, primarily serves as an amendment to correct an inadvertent filing error related to an Interactive Data File for the quarter ended June 30, 2010. The company is a large accelerated filer, indicating its significant market capitalization and regular filing history. This amendment does not alter the previously reported financial performance for the quarter but addresses a procedural issue with an exhibit. Investors should note that this filing is an amendment to correct a data file exhibit and does not introduce new financial information or materially change the previously reported results for the period ending June 30, 2010. The company confirms it has filed all required reports and is not a shell company. The outstanding common shares as of July 20, 2010, were approximately 1.15 billion.

Financial Highlights

47 data points

Beta

Revenue

$5.75B

0.8% Gross Margin

Net Income

$1.35B

0.2% Net Margin

EPS (Diluted)

$1.22

Total Assets

$27.72B

Cash & Equivalents

$5.16B

Free Cash Flow

$1.91B

Financial Statements

Beta

Revenue	$5.75B
Cost of Revenue	$1.02B
Gross Profit	$4.72B
R&D Expenses	$1.19B
SG&A Expenses	$1.76B
Interest Expense	$47.50M
Net Income	$1.35B
EPS (Basic)	$1.22

Key Highlights

1Amendment No. 1 to Form 10-Q for the quarter ended June 30, 2010, filed on August 1, 2010.
2The primary purpose of the amendment is to replace an Interactive Data File (Exhibit 101) that was inadvertently filed incorrectly.
3This filing confirms Eli Lilly and Company is a large accelerated filer.
4The company has submitted all required reports and is not a shell company.
5As of July 20, 2010, Eli Lilly had approximately 1,153,140,311 shares of common stock outstanding.
6No changes to the previously reported financial performance or operational results are indicated by this amendment.

ELI LILLY & Co Quarterly Report (Amendment) for Q2 Ended Jun 30, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions